Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Neurizon Therapeutics Ltd

NUZ.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Micro Cap Analyst: STRONG BUY

Last Close

$0.04

▲ +1.64%

Market Cap $33.90M · Vol 590.91K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$33.90M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

54.55

Momentum

Beta

1.60

vs Market

52W High

$0.12

59.17% below

52W Low

$0.04

13.58% above

Volume

590.91K

Avg 622.67K

P/B

27.93

Price-to-book

ROE

N/A

Return on equity

Free Float

75.60%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Neurizon Therapeutics Ltd (NUZ.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NUZ.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.59%

-3.13%

-10.14%

-33.33%

YTD

-27.06%

-62.91%

-5.23%

-29.93%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-10,918,579.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-214.34% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	27.93
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	775.10M

Technical Indicators

50-Day SMA	$0.04
200-Day SMA	$0.06
RSI (14)	54.55
Beta	1.60
52-Week High	$0.12
52-Week Low	$0.04

Volume Today	590.91K
Avg Daily Volume (30D)	622.67K
Relative Volume	0.95x
Volatility (10D)	65.83
Volatility (30D)	56.94
Free Float	75.60%

Analyst Consensus

STRONG BUY

Current Price $0.04

Mean Target $0.14

52W Low$0.04 52W High$0.12

Current

Target

$0.04 $0.12

Current Analyst target

+226.32% upside potential · 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SC5SW8

ISINAU0000357261

CountryAustralia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateSep 1, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.